Key result
Partial prothrombinase shortens clotting time and activates coagulation equivalently to FEIBA in preclinical models.
A complex consisting of activated factor X (FX) (enzyme) and prothrombin (substrate), both highly purified from human plasma and virus inactivated, was formulated, characterised biochemically as well as in animal studies, and given the name Partial Prothrombinase (PPT). In vitro, PPT shortened the clotting time of a high-titre human factor VIII (FVIII) inhibitor plasma in a manner similar to that of the activated prothrombin complex concentrate FEIBA and triggered coagulation in plasma samples in which factor V (FV) is present. In vivo, the ability of PPT to activate coagulation in both chimpanzees and baboons was equivalent to that of FEIBA. PPT also triggered coagulation in a von Willebrand factor(vWF)-deficient dog and controlled bleeding in rabbits with antibody-induced haemophilia A. Thus, studying the mechanism of action of PPT also explains the therapeutic principle of FEIBA.
No takes yet. Share an insight, caveat, or question.
Turecek et al. (1999) studied Haemophilia A and von Willebrand factor deficiency (in vitro and animal models). Partial Prothrombinase (PPT, a complex of activated factor X and prothrombin) vs. FEIBA (activated prothrombin complex concentrate) was evaluated on Coagulation activation, clotting time, and bleeding control. Partial Prothrombinase (FXa and prothrombin complex) shortened FVIII inhibitor plasma clotting time and activated coagulation in animal models equivalently to FEIBA.
Synapse has enriched 5 related papers. Consider them for comparative context: